Glaxo drug shown to delay ovarian cancer relapse

By Deena Beasley CHICAGO (Reuters) – A cancer drug sold by GlaxoSmithKline was shown in a clinical trial to extend by several months the length of time ovarian cancer patients lived without their disease worsening. The findings suggest that the oral drug, Votrient, could be used as a “maintenance” therapy for many ovarian cancer patients whose disease had returned after initial surgery and chemotherapy. “This is the first positive clinical trial for a targeted agent in ovarian cancer,” said lead study author Dr. …